Chengdu Kanghua Biological Products Co., Ltd.

SZSE:300841 Stock Report

Market Cap: CN¥6.8b

Chengdu Kanghua Biological Products Valuation

Is 300841 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300841 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300841 (CN¥50.98) is trading above our estimate of fair value (CN¥34.43)

Significantly Below Fair Value: 300841 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300841?

Other financial metrics that can be useful for relative valuation.

300841 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.7x
Enterprise Value/EBITDA8.2x
PEG Ratio0.8x

Price to Earnings Ratio vs Peers

How does 300841's PE Ratio compare to its peers?

The above table shows the PE ratio for 300841 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average34.3x
300685 Amoy Diagnostics
27.1x20.8%CN¥7.3b
300406 Beijing Strong BiotechnologiesInc
14.9x19.7%CN¥8.0b
002880 Shenzhen Weiguang Biological Products
28.3x15.3%CN¥6.2b
600645 Vcanbio Cell & Gene Engineering
66.9xn/aCN¥7.3b
300841 Chengdu Kanghua Biological Products
12.2x15.6%CN¥6.8b

Price-To-Earnings vs Peers: 300841 is good value based on its Price-To-Earnings Ratio (12.2x) compared to the peer average (34.3x).


Price to Earnings Ratio vs Industry

How does 300841's PE Ratio compare vs other companies in the CN Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a34.6%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a34.6%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 300841 is good value based on its Price-To-Earnings Ratio (12.2x) compared to the CN Biotechs industry average (33.6x).


Price to Earnings Ratio vs Fair Ratio

What is 300841's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300841 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12.2x
Fair PE Ratio22.3x

Price-To-Earnings vs Fair Ratio: 300841 is good value based on its Price-To-Earnings Ratio (12.2x) compared to the estimated Fair Price-To-Earnings Ratio (22.3x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300841 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥50.98
CN¥81.68
+60.2%
4.1%CN¥85.00CN¥78.35n/a2
Jul ’25CN¥51.68
CN¥81.68
+58.0%
4.1%CN¥85.00CN¥78.35n/a2
Jun ’25CN¥57.90
CN¥81.68
+41.1%
4.1%CN¥85.00CN¥78.35n/a2
May ’25CN¥62.82
CN¥102.01
+62.4%
16.7%CN¥119.02CN¥85.00n/a2
Apr ’25CN¥62.38
CN¥96.33
+54.4%
16.9%CN¥119.02CN¥81.97n/a3
Mar ’25CN¥62.97
CN¥84.99
+35.0%
3.5%CN¥88.00CN¥81.97n/a2
Feb ’25CN¥55.45
CN¥84.99
+53.3%
3.5%CN¥88.00CN¥81.97n/a2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.